REVIVA PHARMACEUTICALS HOLDINGS, INC.

Reviva Pharmaceuticals Holdings, Inc. (Nasdaq: RVPH) is a clinical-stage biopharmaceutical company operating in the pharmaceutical and biotechnology sector that emerged as a public entity through a SPAC combination. The company, which became publicly traded circa 2019, filed a Form 10-Q with the SEC on October 8, 2019, under accession number 0001144204-19-047666, reflecting its post-combination operating status as a de-SPAC entity. Reviva is focused on developing novel treatments for central nervous system and metabolic disorders. Sign up on SpacDesk for full data on RVPH, including deal history, filing timelines, and post-merger performance metrics.